APA (7th ed.) Citation

NG, A., RM, A., AA, A., M, A., R, K., H, A., & AA, A. (2021). Aflibercept versus Ranibizumab as a Second Line Therapy After Bevacizumab for Diabetic Macular Edema. Dove Medical Press.

Chicago Style (17th ed.) Citation

NG, Alsaedi, Alselaimy RM, Alshamrani AA, AlAjmi M, Khandekar R, Al-Dhibi H, and Al-Abdullah AA. Aflibercept Versus Ranibizumab as a Second Line Therapy After Bevacizumab for Diabetic Macular Edema. Dove Medical Press, 2021.

MLA (8th ed.) Citation

NG, Alsaedi, et al. Aflibercept Versus Ranibizumab as a Second Line Therapy After Bevacizumab for Diabetic Macular Edema. Dove Medical Press, 2021.